T1	Participants 489 676	patients were post-menopausal, previously untreated with hormone therapy, and with tumor receptor status determined immediately before randomization; all had objectively evaluable lesions
T2	Participants 152 220	January 1985 to September 1988, 60 women with advanced breast cancer
